Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematologic Neoplasms | 9 | 2024 | 344 | 3.530 |
Why?
|
| Prostate-Specific Antigen | 5 | 2016 | 337 | 1.660 |
Why?
|
| Germ-Line Mutation | 10 | 2024 | 346 | 1.500 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2024 | 2356 | 1.490 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2024 | 798 | 1.470 |
Why?
|
| Early Detection of Cancer | 5 | 2016 | 419 | 1.400 |
Why?
|
| Mesothelioma | 4 | 2024 | 320 | 1.230 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2024 | 130 | 1.100 |
Why?
|
| Life Expectancy | 3 | 2015 | 88 | 1.020 |
Why?
|
| Neoplasms | 5 | 2023 | 3054 | 0.910 |
Why?
|
| Myeloproliferative Disorders | 2 | 2024 | 133 | 0.800 |
Why?
|
| Prostatic Neoplasms | 5 | 2016 | 1734 | 0.700 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 64 | 0.690 |
Why?
|
| Leukemia | 2 | 2023 | 322 | 0.660 |
Why?
|
| Mass Screening | 4 | 2016 | 645 | 0.600 |
Why?
|
| Precision Medicine | 2 | 2021 | 409 | 0.590 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2024 | 359 | 0.560 |
Why?
|
| Lymphoma | 1 | 2016 | 266 | 0.490 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 105 | 0.490 |
Why?
|
| Testosterone | 1 | 2016 | 272 | 0.490 |
Why?
|
| Humans | 39 | 2024 | 89613 | 0.480 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2023 | 488 | 0.470 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 606 | 0.420 |
Why?
|
| Radiosurgery | 1 | 2016 | 287 | 0.410 |
Why?
|
| Germ Cells | 4 | 2023 | 130 | 0.410 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2024 | 174 | 0.410 |
Why?
|
| Peritoneal Neoplasms | 2 | 2024 | 181 | 0.400 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 1064 | 0.390 |
Why?
|
| Venous Thromboembolism | 2 | 2024 | 159 | 0.380 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 260 | 0.360 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 4 | 2024 | 59 | 0.350 |
Why?
|
| Mutation | 5 | 2024 | 4160 | 0.310 |
Why?
|
| Decision Making | 1 | 2014 | 669 | 0.300 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1541 | 0.270 |
Why?
|
| Age Factors | 4 | 2018 | 1877 | 0.260 |
Why?
|
| Selection Bias | 2 | 2016 | 36 | 0.260 |
Why?
|
| Male | 13 | 2024 | 42488 | 0.250 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2024 | 17 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2022 | 24 | 0.240 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 65 | 0.230 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2024 | 24 | 0.230 |
Why?
|
| CD47 Antigen | 1 | 2024 | 23 | 0.230 |
Why?
|
| Thrombocytopenia | 2 | 2024 | 187 | 0.230 |
Why?
|
| Aged | 8 | 2024 | 19158 | 0.220 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 91 | 0.220 |
Why?
|
| DNA Helicases | 1 | 2023 | 84 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 585 | 0.210 |
Why?
|
| Middle Aged | 8 | 2024 | 26012 | 0.200 |
Why?
|
| Genomics | 3 | 2023 | 775 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 836 | 0.200 |
Why?
|
| Syndrome | 1 | 2023 | 449 | 0.200 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 64 | 0.200 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 3021 | 0.200 |
Why?
|
| Blood Platelet Disorders | 1 | 2021 | 12 | 0.200 |
Why?
|
| Prognosis | 5 | 2024 | 3785 | 0.190 |
Why?
|
| Sulfonamides | 1 | 2024 | 318 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 412 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 312 | 0.190 |
Why?
|
| Megakaryocytes | 1 | 2021 | 36 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 592 | 0.190 |
Why?
|
| Pulmonary Embolism | 1 | 2024 | 229 | 0.180 |
Why?
|
| Neutropenia | 1 | 2021 | 214 | 0.180 |
Why?
|
| Genetic Testing | 3 | 2022 | 539 | 0.180 |
Why?
|
| Appendicitis | 1 | 2021 | 65 | 0.180 |
Why?
|
| Dendritic Cells | 1 | 2024 | 451 | 0.180 |
Why?
|
| Hematopoiesis | 1 | 2021 | 168 | 0.180 |
Why?
|
| United States | 5 | 2024 | 7050 | 0.170 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 395 | 0.170 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 118 | 0.170 |
Why?
|
| Adult | 9 | 2024 | 26704 | 0.160 |
Why?
|
| Risk | 2 | 2021 | 655 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 5 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2021 | 423 | 0.150 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 60 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6771 | 0.140 |
Why?
|
| Health Surveys | 2 | 2015 | 240 | 0.140 |
Why?
|
| Female | 7 | 2024 | 46401 | 0.140 |
Why?
|
| Orchiectomy | 1 | 2016 | 62 | 0.130 |
Why?
|
| Gene Frequency | 1 | 2018 | 687 | 0.130 |
Why?
|
| Standard of Care | 1 | 2016 | 65 | 0.130 |
Why?
|
| Androgen Antagonists | 1 | 2016 | 138 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2015 | 152 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 868 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2015 | 344 | 0.110 |
Why?
|
| Mental Recall | 1 | 2015 | 162 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 2364 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 2503 | 0.110 |
Why?
|
| Genome, Human | 1 | 2018 | 791 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2015 | 234 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 205 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1446 | 0.100 |
Why?
|
| Survival Rate | 1 | 2016 | 1887 | 0.100 |
Why?
|
| Biopsy | 1 | 2015 | 1183 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2018 | 1380 | 0.100 |
Why?
|
| Health Status | 1 | 2014 | 371 | 0.100 |
Why?
|
| Research Design | 1 | 2015 | 589 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1725 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2016 | 555 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 774 | 0.090 |
Why?
|
| Young Adult | 2 | 2024 | 6368 | 0.090 |
Why?
|
| Logistic Models | 1 | 2014 | 1214 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 952 | 0.090 |
Why?
|
| Testicular Neoplasms | 1 | 2011 | 113 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2011 | 216 | 0.090 |
Why?
|
| Smoking | 1 | 2014 | 625 | 0.080 |
Why?
|
| Risk Factors | 2 | 2024 | 5517 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1727 | 0.080 |
Why?
|
| Clathrin | 1 | 2007 | 29 | 0.070 |
Why?
|
| Protein Structure, Quaternary | 1 | 2007 | 101 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2024 | 9127 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1050 | 0.060 |
Why?
|
| Blast Crisis | 1 | 2024 | 37 | 0.060 |
Why?
|
| GATA2 Transcription Factor | 1 | 2023 | 14 | 0.060 |
Why?
|
| Philadelphia Chromosome | 1 | 2024 | 42 | 0.060 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2024 | 109 | 0.060 |
Why?
|
| World Health Organization | 1 | 2023 | 108 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2023 | 64 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2024 | 280 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2023 | 79 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 103 | 0.050 |
Why?
|
| Pedigree | 1 | 2024 | 970 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2021 | 27 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2023 | 213 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2022 | 182 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2021 | 109 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2024 | 8218 | 0.050 |
Why?
|
| Genetic Counseling | 1 | 2021 | 101 | 0.050 |
Why?
|
| Emergencies | 1 | 2021 | 122 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 265 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 142 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2024 | 428 | 0.040 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 83 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 604 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 386 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1353 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 791 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 294 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2884 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 326 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 550 | 0.030 |
Why?
|
| Alleles | 1 | 2018 | 1137 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 889 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2449 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 4309 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 1762 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2297 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2012 | 90 | 0.020 |
Why?
|
| Americas | 1 | 2011 | 19 | 0.020 |
Why?
|
| Asia | 1 | 2011 | 100 | 0.020 |
Why?
|
| Africa | 1 | 2011 | 101 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 101 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 9305 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 11832 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 322 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 203 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 27481 | 0.020 |
Why?
|
| Sarcosine | 1 | 2007 | 2 | 0.020 |
Why?
|
| Detergents | 1 | 2007 | 34 | 0.020 |
Why?
|
| Cattle | 1 | 2007 | 378 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1598 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7216 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 338 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 740 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 5337 | 0.010 |
Why?
|